JACC

Applied Therapeutics Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
Sale, FDA, PRV, American College, Diabetic cardiomyopathy, Investment, Priority review, ACC, NDA, Food, Research, Marketing, New Drug Application, MAA, CHMP, Doctor of Philosophy, Disease, Journal, ChromeOS, PDUFA, Patient, Treatment, EMA, JACC, Therapy, HF, European Medicines Agency, Ageing, Pharmaceutical industry

As a result, the Company now expects a decision by the EMA in early first quarter of 2025.

Key Points: 
  • As a result, the Company now expects a decision by the EMA in early first quarter of 2025.
  • Mr. Hooks brings over 30 years of biopharmaceutical experience in leadership, rare disease marketing and sales roles to Applied Therapeutics.
  • Presented Full Results from Phase 3 ARISE-HF Study of AT-001 (caficrestat) in Diabetic Cardiomyopathy at the 2024 American College of Cardiology Annual Scientific Session.
  • Following the presentation, the full study results were published in the Journal of the American College of Cardiology (JACC).

Newsweek Selects Caristo Diagnostics as One of World's Best Digital Health Companies

Retrieved on: 
月曜日, 4月 29, 2024
Inflammation, Coronary artery disease, Holon, Heart, Newsweek, Disease, Cardiovascular Research, Stroke, Diagnosis, Digital health, Patient, Splenic infarction, Cari, JACC, European Heart Journal, CCTA, Algorithm, Health, Medical device

OXFORD, England, April 29, 2024 /PRNewswire/ -- Caristo Diagnostics , a leading cardiac disease diagnostics company, has been named by Newsweek as one of World's Best Digital Health Companies in diagnostics.

Key Points: 
  • OXFORD, England, April 29, 2024 /PRNewswire/ -- Caristo Diagnostics , a leading cardiac disease diagnostics company, has been named by Newsweek as one of World's Best Digital Health Companies in diagnostics.
  • Newsweek's inaugural ranking of the World's Best Digital Health Companies includes 400 companies in seven segments including diagnostics, health records, medical management and telehealth.
  • The ranking is based on in-depth analysis of thousands of companies' financial performance and traffic data for websites and apps.
  • "Caristo is honored to be recognized by Newsweek as one of the World's Best Digital Health Companies.

Newsweek Selects Caristo Diagnostics as One of World's Best Digital Health Companies

Retrieved on: 
月曜日, 4月 29, 2024
Inflammation, Coronary artery disease, Holon, Heart, Newsweek, Disease, Cardiovascular Research, Stroke, Diagnosis, Digital health, Patient, Splenic infarction, Cari, JACC, European Heart Journal, CCTA, Algorithm, Health, Medical device

OXFORD, England, April 29, 2024 /PRNewswire/ -- Caristo Diagnostics , a leading cardiac disease diagnostics company, has been named by Newsweek as one of World's Best Digital Health Companies in diagnostics.

Key Points: 
  • OXFORD, England, April 29, 2024 /PRNewswire/ -- Caristo Diagnostics , a leading cardiac disease diagnostics company, has been named by Newsweek as one of World's Best Digital Health Companies in diagnostics.
  • Newsweek's inaugural ranking of the World's Best Digital Health Companies includes 400 companies in seven segments including diagnostics, health records, medical management and telehealth.
  • The ranking is based on in-depth analysis of thousands of companies' financial performance and traffic data for websites and apps.
  • "Caristo is honored to be recognized by Newsweek as one of the World's Best Digital Health Companies.

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
日曜日, 4月 7, 2024
Uric acid, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, Atherosclerosis, FAHA, Cleveland Clinic, Bempedoic acid, Ezetimibe, Therapy, Anemia, Pain, MACE, Sinusitis, ACC, FOMA, FNLA, FACC, Obesity, Cardiovascular disease, Esperion Therapeutics, Abdominal pain, Risk, Gout, Spasm, Woman, American College, Body mass index, ESPR, Back pain, Outcome, ATP, Safety, Fatigue, Arthralgia, ANN, Angioedema, Kidney, Journal, Constipation, University, Adverse event, Pregnancy, CLEAR, Rash, MPH, Rupture, FDA, Molina Healthcare, JACC, Hypersensitivity, Health, Circulatory system, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Dietary supplement

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Retrieved on: 
土曜日, 4月 6, 2024
MB, TGS, High, Science, CH.B, Risk, Research, American College, MACE, Professional corporation, IPE, JACC, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted two data presentations at ACC.24 describing the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) on reducing MACE (Major Adverse Cardiovascular Events) in patients with baseline high or low Lipoprotein(a) [Lp(a)] levels, as well as reducing the risk of cardiovascular (CV) events in patients irrespective of baseline LDL-C level. The REDUCE-IT analysis results relating Lp(a) concentrations with CV risk were also published online today in the Journal of the American College of Cardiology (JACC).

Key Points: 
  • There are no treatments currently approved to reduce residual CV risk on top of contemporary medical therapy in patients with high Lp(a) levels.
  • In this subanalysis, there were 7,026 REDUCE-IT patients with baseline Lp(a) data and a median Lp(a) value of 11.6 (Q1-Q3: 5.0-37.4) mg/dL.
  • Importantly, the treatment benefit of IPE was evident across subgroups with both high (≥50 mg/dL) and low (
  • Limitations are that randomization was not stratified by baseline LDL-C, however, baseline characteristics were similar among the two baseline LDL-C subgroups.

Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024

Retrieved on: 
木曜日, 4月 4, 2024
Diabetic cardiomyopathy, Patient, Journal, Diabetes, American College, Treatment, Therapy, Safety, ACC, JACC, Pharmaceutical industry

The presentation at ACC will also include important data on progression to overt heart failure and other secondary outcome measures.

Key Points: 
  • The presentation at ACC will also include important data on progression to overt heart failure and other secondary outcome measures.
  • AT-001 treatment prevented progression to overt heart failure in patients with DbCM as compared to placebo (p=0.0285).
  • The oral presentation at ACC will be followed by simultaneous publication of the study results in the Journal of the American College of Cardiology Journal (JACC).
  • A Selective Aldose Reductase Inhibitor (AT-001) For the Treatment of Diabetic Cardiomyopathy: Primary Results of the Phase 3 Randomized Controlled ARISE-HF Study
    Monday, April 8, 2024, 8:30 – 9:45 am ET, Main Tent (Hall B1)

Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Retrieved on: 
月曜日, 3月 11, 2024
Health, Medical Devices, Surgery, Clinical Trials, Research, Science, Cardiology, Registry, CRT, Aortic stenosis, TVT, Patient, Journal, Stroke, Mortality, Ultra, Oakland University, MD, Cardiovascular disease, American College, TAVR, Arrest, JACC, PVL, Medical imaging

Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.
  • In a second study presented during the late-breaking clinical trials session, small Edwards SAPIEN TAVR valves demonstrated equally excellent outcomes at 3 years as compared to larger SAPIEN TAVR valve sizes.
  • The study found that all Edwards TAVR platforms demonstrated excellent PVL results.
  • An analysis of 8,100 propensity matched patients across more than 800 sites in the United States found that patients treated with a 20mm Edwards SAPIEN valve demonstrated excellent all-cause mortality and stroke outcomes at 3-years, equivalent to those receiving 23, 26 and 29mm SAPIEN valve sizes.

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
火曜日, 2月 6, 2024
Inflammation, Growth, Liver cancer, Immunity, Immunotherapy, Research, JACC, Therapy, Prevalence, Tan, Metabolic syndrome, PNAS, MOA, JAMA Oncology, Sorafenib, Fibrosis, Bevacizumab, Immunogenic cell death, Laboratory, ICIS, Metabolism, Pembrolizumab, Neoplasm, MASH, Nivolumab, Hepatology, Liver, Cancer

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
火曜日, 2月 6, 2024
Inflammation, Growth, Liver cancer, Immunity, Immunotherapy, Research, JACC, Therapy, Prevalence, Tan, Metabolic syndrome, PNAS, MOA, JAMA Oncology, Sorafenib, Fibrosis, Bevacizumab, Immunogenic cell death, Laboratory, ICIS, Metabolism, Pembrolizumab, Neoplasm, MASH, Nivolumab, Hepatology, Liver, Cancer

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

Retrieved on: 
水曜日, 1月 24, 2024
Cardiology, Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Medical Devices, Software, Artificial Intelligence, Genetics, Nuclear medicine, Entrepreneurship, Artificial intelligence, Patient, Internal medicine, Research, American College of Physicians, MD, Cardio, Emory University, JACC, Innovation, University, Algorithm, Journal of Clinical Investigation, FACC, ACP, ACC, Journal, NIH, Cardiovascular disease, Bachelor of Science, Hospital, Society for Vascular Surgery, Mount Sinai School, American College, Growth, Medical device

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.
  • The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company’s continued growth and market expansion.
  • “I am excited to join Cardio Diagnostics and contribute to the company’s mission of improving cardiovascular health,” said Dr. Ramjee.
  • Dr. Ramjee will also work to raise awareness of Cardio Diagnostics’ innovative technologies and their potential to improve patient care.